Strong expression of at least one of the three D-type cyclins is common in human cancers. While the cyclin D1 and D3 genes (CCND1 and CCND3) are recurrently involved in genomic rearrangements, especially in B-cell lymphoid neoplasias, no clear involvement of the cyclin D2 gene (CCND2) has been reported to date. Here, we identified chromosomal translocations targeting the CCND2 locus at 12p13, and the T-cell receptor beta (TCRB) or the TCRA/D loci in T-cell acute lymphoblastic leukemias (T-ALLs). Expression analysis demonstrated dramatic cyclin D2 overexpression in the translocated cases (n ¼ 3) compared to other T-ALLs (total, n ¼ 89). In order to evaluate dysregulation in T-ALL with respect to normal T-cell differentiation, we analyzed CCND2 expression in normal purified human thymic subpopulations. CCND2 levels were downregulated through progression from the early stages of human T-cell differentiation, further suggesting that the massive and sustained expression in the CCND2-rearranged T-ALL cases was oncogenic. Association with other oncogene expression (TAL1, HOXAs, or TLX3/HOX11L2), NOTCH1 activating mutations, and/or CDKN2A/p16/ARF deletion, showed that cyclin D2 dysregulation could contribute to multi-event oncogenesis in various T-ALL groups. This report is the first clear evidence of a direct involvement of cyclin D2 in human cancer due to recurrent somatic genetic alterations.
Introduction
T-cell acute lymphoblastic leukemias (T-ALLs) are highly malignant tumors that derive from T-cell progenitors. 1 Immunophenotypic and gene expression analyses of leukemic cells have revealed heterogeneity that is partially related to distinct stages of T-cell maturation arrest. [2] [3] [4] [5] An increasing number of oncogenes have been involved in T-ALLs, further demonstrating the complexity of T-ALL oncogenesis and the requirement for several cooperative oncogenic events. 1, 6 Transcription factor oncogenes are frequently aberrantly activated in T-ALL, including TAL1, TLX1/HOX11, TLX3/HOX11L2, HOXAs, and the CALM-AF10 and MLL fusion genes. 1, 6 Correlation between oncogene expression and large-scale expression profiles has allowed to define distinct oncogenic T-ALL subgroups. 4, 5 In addition, the tumor suppressor locus CDKN2A/p16/ARF is deleted and/or mutated in most T-ALL cases, 7 and NOTCH1 is activated by mutations in half the T-ALLs. 8 Notably, most if not all these genes had been initially involved in T-ALL oncogenesis by their involvement in recurrent chromosomal translocations. Indeed, elucidation of recurrent chromosomal rearrangements is a major way to pinpoint genes involved in oncogenesis. 9 The three D-type cyclins (D1, D2, and D3) are key regulators of the progression from G1-to S-phase of the cell cycle. 10, 11 In accordance with their role in cell proliferation, many human cancers strongly express at least one of the D-type cyclins, including cyclin D2, [12] [13] [14] suggesting that D cyclins deregulated expression play an oncogenic role. 15, 16 Moreover, the cyclin D1 and D3 genes (CCND1 and CCND3, respectively) have been shown to be targeted by recurrent genomic rearrangements, especially in B-cell lymphoid neoplasias. Hence, cyclin D1 is overexpressed in mantle cell lymphoma due to the t(11;14)(q13;q32). 15, 17 In multiple myeloma, t(11;14)(q13;q32) and t(6;14)(p21;q32) can target the CCND1 and CCND3 loci, respectively. [18] [19] [20] Systematic D cyclins expression analysis and large-scale expression patterns have further suggested that direct or indirect transcriptional activation of cyclins D1, D2, and/or D3 is critical in myeloma oncogenesis.
14 By contrast to CCND1 and CCND3, no clear involvement of CCND2 in recurrent genomic rearrangement has been reported to date in human cancer. Here, we report evidence of a direct targeting of the CCND2 locus at 12p13 by recurrent chromosomal translocations to the T-cell receptor (TCR) loci in T-ALL, leading to cyclin D2 dysregulation.
Materials and methods

Human samples
T-ALL patients (53 children, 36 adults) were diagnosed and treated at Saint-Louis hospital, Paris, France. Informed consent was obtained from the patients and/or relatives. All samples were previously characterized and classified for oncogenic groups according to immunophenotypic data, oncogene expression and global gene expression analysis. 5 Normal thymic subpopulations (10 fractions) were purified from human thymus obtained after cardiac surgery as previously described. 5 
Cytogenetic and genomic analyses
Interphasic FISH analyses were performed from cryopreserved leukemic cells. TCRB flanking FISH probes have been previously described. 5 Other flanking FISH BAC probes were: CCND2, RP11-320N7, and RP11-388F6; TCRA/D, RP11-689J19 (AL161747), and CTD-2555K7; ETV6/TEL, RP11-94N22, and RP11-297N18. The CDKN1B/KIP1 locus was analyzed using the RP11-180M15 (AC008115) FISH probe. All BAC and PAC clones were obtained from Research Genetics (Invitrogen, www.invitrogen.com/). Whole chromosome painting FISH probes WCP7, WCP12, and WCP14 were used (VysisAbbott Laboratories, http://www.vysis.com/). Molecular characterization of the TCRB translocation was performed from genomic DNA in case TL48, using an inverse PCR method previously reported.
5 CDKN2A/p16/ARF deletion and NOTCH1 mutation analyses were performed by FISH and DNA sequencing, respectively, as reported. 5, 8 Real-time quantitative PCR analysis Expression analysis of the CCND2 gene was performed using Taqman s methods (Applied Biosystems, http://www.applied biosystems.com/) and normalization with the housekeeping gene GUS. Primers and probes were: CCND2, 2404-F:
Immunoblot analysis
In all samples, 30 mg of total protein extracts from leukemic cells, and PHA-stimulated peripheral blood lymphocytes (PBLs)
were analyzed by standard procedures using anticyclin D2 (sc-181), anticyclin D3 (sc-6283), anticyclin D1 (sc-20044), and antiactin (sc-1616) antibodies, all from Santa Cruz (http:// www.scbt.com/), and appropriate secondary peroxydase-conjugated antibodies.
Results and discussion
TCR loci are frequently involved in chromosomal translocations in T-ALL, leading to oncogene transcriptional activation. In order to identify new genomic events and oncogenes in T-ALL, we performed interphasic FISH on cryopreserved leukemic cells from T-ALL samples using T-cell receptor beta (TCRB) flanking probes. A TCRB chromosomal rearrangement was identified in the T-ALL case TL48 ( Figure 1a ). Leukemic metaphases demonstrated a t(7;12)(q34;p13) translocation ( Figure 1b and Supplementary Figure S1 ). Molecular amplification of the Db1-derivative breakpoint fragment was performed from genomic DNA using inverse PCR ( Figure 1c ). Sequence analysis suggested V(D)J-mediated mechanism of translocation, and allowed identification of the chromosomal partner region ( Figure 1d ). (7)t(7;12)(q34;p13) breakpoint and corresponding germline (GL) regions. Recognition sequence signal heptamers are indicated (7-mer); untemplated nucleotides (N-and P-diversity) are typed in lowercase, Db1 sequence is bolded. (e) Chromosomal breakpoint region at 12p13.32. A 550 Mb interval centered by the translocation breakpoint (BP) is shown according to UCSC Genome Bioinformatics (Human May 2004 Assembly, http://genome.ucsc.edu). The CCND2 gene is indicated. Other referred genes in the 550 Mb interval are shown; they are located centromeric from CCND2, and are, from telomere to centromere, C12orf5, FGF23, FGF6, C12orf4, and RAD51AP1. None of these genes was deregulated in the CCND2-rearranged cases compared to other T-ALL, based on microarray data (not shown). The RP11-320N7 and RP11-388F6 BAC clones are indicated and were used for subsequent CCND2 FISH analysis.
Cyclin D2 (CCND2) translocations in T-ALLs
analysis using multiple combinations of CCND2 and TCRB flanking probes showed that the translocation was balanced (data not shown). Therefore, this new chromosomal translocation transposed the TCRB locus at the vicinity of the CCND2 gene.
We analyzed CCND2 gene expression using real-time quantitative PCR (RQ-PCR) in a series of 89 T-ALLs, including the TL48 case. These cases have been previously characterized (immunophenotypic data and oncogene expression), and oncogenic subgroups were defined based on gene expression TL71  TL24  TL54  TL65  TL48  TL12  PBL- translocations are boxed. All T-ALL cases were previously classified in oncogenic subgroups according to immunophenotypic data, genomic data and global gene expression analysis. 5 Patients were subsequently referred by increasing TL numbers (TL1-TL89) related to this classification. 5 Case numbers and oncogenic subgroups (TAL-RA, TAL1-related sub-group A; TAL-RB, TAL1-related sub-group B; MLL, MLL-rearranged; CALM-AF10; HOXA-related; TLX1; TLX3, and Immature) are indicated below the histogram. Early T-ALL refers to cases with co-expression of the most immature thymic genes and includes half the TLX3-related cases, 5 CCND2 expression levels are shown as the ratio (copy number in a given sample):(median copy number in the series), as determined using the DC t method; the dotted line indicates an arbitrary threshold value at 2.5. RQ-PCR values were consistent with microarray data for CCND2 probesets (not shown). (b) Interphasic FISH using CCND2 flanking probes in case TL65 showed dissociation of the probes, detecting a chromosomal translocation; see also additional karyotypic data in Supplementary Figure S1 . (c) Representative immunoblot analysis of cyclin D2 and cyclin D3 proteins. The three CCND2-rearranged cases (TL12, TL48 and TL65) were analyzed along with control T-ALL cases (TL24, TL54 and TL71, from the TAL1-related, TLX1 and TLX3 oncogenic subgroups, respectively), and PHA-stimulated PBLs. Actin levels were used as loading control. No expression of cyclin D1 was found in the T-ALL samples (not shown). 
E Clappier et al analysis. 5 TL48 leukemic cells showed dramatic strong expression of CCND2 compared to levels in other T-ALLs (Figure 2a) . Thus, overexpression in this case was most probably related to transcriptional activation due to TCRB regulatory sequences. Of note, a unique case of chromosomal translocation involving the CCND2 promoter and IGH genes had been reported in a chronic lymphocytic leukemia case but no expression analysis had been performed. 21 In addition to TL48, several T-ALL cases showed relatively strong CCND2 expression (Figure 2a) . In a search for additional cases of CCND2 rearrangement, we performed interphasic FISH using CCND2 flanking probes at 12p13.32 in the cases showing the highest CCND2 mRNA levels (cases TL12, TL43, TL44, TL62, TL65, TL70, TL76, TL80, TL84, and TL87; insufficient materials for TL69 and TL78). Chromosomal rearrangement involving the CCND2 locus was detected in two more cases, TL12 and TL65, precisely those with the highest CCND2 levels in addition to TL48 (Figure 2a and b) . Using multiple combinations of CCND2, TCRA/D, and TCRB flanking FISH probes, we found that the CCND2 gene was juxtaposed to the TCRA/D locus in case TL12 and to the TCRB in case TL65 (not shown). Consistently, metaphase analysis demonstrated reciprocal chromosomal translocations t(12;14)(p13;q11) and t(7;12)(q34;p13), in cases TL12 and TL65, respectively (Supplementary Figure S1 ). Of note, such chromosomal translocations had been rarely but recurrently reported in T-ALL, but target genes were unresolved (see Mitelman Database of Chromosome Aberrations in Cancer, http://cgap.nci.nih.gov/Chromosomes/ Mitelman). [22] [23] [24] The TEL1/ETV6 and KIP1/CDKN1B genes, located more than 8 Mb centromeric to the CCND2 locus, have been previously involved in various 12p13.2 genomic rearrangements in leukemia, including the t(7;12)(q36;p13) in infant. [25] [26] [27] [28] We analyzed the TEL1/ETV6 and KIP1/CDKN1B loci by FISH in our three T-ALL cases, and did not detect any abnormalities (data not shown). We also examined expression of other genes located at the vicinity of the breakpoint at 12p13.32 (C12orf5, FGF23, FGF6, C12orf4, and RAD51AP1), using microarray data; in contrast to the CCND2 gene, these genes were not dysregulated in the CCND2-rearranged cases compared to other T-ALLs (data not shown). Considering that D cyclins protein levels can be regulated at the post-transcriptional level, we performed cyclin D2 immunoblot. As expected, leukemic cells from the CCND2-translocated cases expressed high amounts of cyclin D2 protein compared to other T-ALLs (Figure 2c) . Therefore, we concluded that the CCND2 gene was the molecular target at 12p13 of the recurrent chromosomal translocations described here in T-ALL, leading to cyclin D2 transcriptional activation.
In order to compare T-ALL leukemic cells with their normal cellular counterparts, we then analyzed CCND2 mRNA levels in human purified thymic subpopulations. CCND2 expression was detected at significant levels in thymic precursors from the earliest stages, the ETP (early thymic progenitors) and Pro-T subsets (see Figure 2d) . It was then downregulated through stages corresponding to beta-selection, and re-expressed at later stages of thymic maturation (Figure 2d ). These results are consistent with data in mouse. 29 In most T-ALL cases, CCND2 expression seemed to reflect this regulation by showing a relatively strong expression in the early T-ALLs (Immature and half the TLX3-related T-ALLs) and low expression in most other T-ALLs (Figure 2a) , as formerly reported. 29 By contrast, the three CCND2-rearranged cases (TL12, TL48 and TL65) demonstrated aberrant CCND2 expression considering oncogenic subgroups (Figure 2a ), further suggesting a role for cyclin D2 dysregulation in leukemogenesis in these cases.
T-ALL oncogenesis involves several classes of oncogenes. [4] [5] [6] [7] [8] [30] [31] [32] [33] We analyzed genomic and molecular data in the three CCND2-rearranged cases, and also found TAL1, HOXAs, or TLX3 oncogene expression, NOTCH1 activating mutations, and/ or CDKN2A/p16/ARF locus deletion (Table 1 ). These data show that cyclin D2 dysregulation can contribute to multievent oncogenesis in cases from various T-ALL sub-groups. Strong expression of D-type cyclins in cancer cells is thought to stimulate cellular proliferation through cell cycle activation. 15, 16 In most T-ALL, the CDKN2A and CDKN2B locus at 9p21 is deleted and/or mutated, 7, 30 leading to suppression of p16 CDKN2A and p15 CDKN2B cell cycle inhibitors and of the p14 ARF -p53 oncogenic stress response pathways. 34 Our data show that CDKN2A/p16/ARF deletion and CCND2 rearrangements are not mutually exclusive, suggesting additive effects on cell cycle and/or cooperation with inactivation of the p14 ARFp53 pathways. In a mouse model of T-ALL, Sicinska et al 29 showed a requirement for cyclin D3, and they also observed CCND3 expression in most human T-ALL. We analyzed D cyclins expression in the three CCND2-rearranged cases and found significant cyclin D3 levels in addition to cyclin D2 (Figure 2c) . Intriguingly, these cases did not display a strong proliferation pattern, as evaluated by microarray expression analysis (cluster C6, 'proliferation and mitosis' signature; 5 data not shown). Considering the tight regulation of cyclin D2 through normal thymic maturation, it is tempting to hypothesize that the massive and sustained expression of cyclin D2 due to chromosomal translocations in T-ALL cases may not simply enhance proliferation but may also impinge on other cellular pathways associated with oncogenesis. Of note, early T-ALLs, which preferentially express CCND2 (Figure 2a) , 29 also display low pattern of proliferation. 5 In conclusion, the present report is the first clear evidence of cyclin D2 dysregulation in human cancer due to recurrent somatic genetic alterations. This reinforces the view that the strong expression of cyclin D2 which is detected in various types of cancer can contribute to oncogenesis, and points to cyclin D2 as a potential target for therapy in these tumors. NOTCH1 mutations in case TL65 were 4724 T/C and 7516 Del CCT InsoTGTGATTGAGTTAGCGCAGAA4, corresponding to mutations 1575L/P (in the HD domain) and 2506CD*stop (in the PEST domain), respectively.
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